Literature DB >> 22850751

Overcoming implementation challenges of personalized cancer therapy.

Funda Meric-Bernstam1, Gordon B Mills.   

Abstract

Personalized cancer therapy is based on the precept that detailed molecular characterization of the patient's tumour and its microenvironment will enable tailored therapies to improve outcomes and decrease toxicity. The goal of personalized therapy is to target aberrations that drive tumour growth and survival, by administering the right drug combination for the right person. This is becoming increasingly achievable with advances in high-throughput technologies to characterize tumours and the expanding repertoire of molecularly targeted therapies. However, there are numerous challenges that need to be surpassed before delivering on the promise of personalized cancer therapy. These include tumour heterogeneity and molecular evolution, costs and potential morbidity of biopsies, lack of effective drugs against most genomic aberrations, technical limitations of molecular tests, and reimbursement and regulatory hurdles. Critically, the 'hype' surrounding personalized cancer therapy must be tempered with realistic expectations, which, today, encompass increased survival times for only a portion of patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22850751     DOI: 10.1038/nrclinonc.2012.127

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  64 in total

Review 1.  Computational methods for discovering structural variation with next-generation sequencing.

Authors:  Paul Medvedev; Monica Stanciu; Michael Brudno
Journal:  Nat Methods       Date:  2009-11       Impact factor: 28.547

Review 2.  Whole cancer genome sequencing by next-generation methods.

Authors:  Jeffrey S Ross; Maureen Cronin
Journal:  Am J Clin Pathol       Date:  2011-10       Impact factor: 2.493

Review 3.  The ethical use of mandatory research biopsies.

Authors:  Erin M Olson; Nancy U Lin; Ian E Krop; Eric P Winer
Journal:  Nat Rev Clin Oncol       Date:  2011-08-02       Impact factor: 66.675

4.  Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

Authors:  C Liedtke; K Broglio; S Moulder; L Hsu; S-W Kau; W F Symmans; C Albarracin; F Meric-Bernstam; W Woodward; R L Theriault; L Kiesel; G N Hortobagyi; L Pusztai; A M Gonzalez-Angulo
Journal:  Ann Oncol       Date:  2009-07-12       Impact factor: 32.976

5.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.

Authors:  Raoul Tibes; Barbara F Piper; Jessica A Smith; Raysenia L James; Martin A Benjamin; Jay H Yim; Ramesh K Ramanathan; Daniel D Von Hoff; R Curtis Bay; Mitesh J Borad
Journal:  Cancer       Date:  2011-01-18       Impact factor: 6.860

7.  Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.

Authors:  Elizabeth A Mittendorf; Yun Wu; Maurizio Scaltriti; Funda Meric-Bernstam; Kelly K Hunt; Shaheenah Dawood; Francisco J Esteva; Aman U Buzdar; Huiqin Chen; Sameena Eksambi; Gabriel N Hortobagyi; Jose Baselga; Ana M Gonzalez-Angulo
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

Review 8.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

9.  Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

Authors:  Michael J Lee; Albert S Ye; Alexandra K Gardino; Anne Margriet Heijink; Peter K Sorger; Gavin MacBeath; Michael B Yaffe
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

10.  Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Authors:  R E Board; G Ellison; M C M Orr; K R Kemsley; G McWalter; L Y Blockley; S P Dearden; C Morris; M Ranson; M V Cantarini; C Dive; A Hughes
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more
  49 in total

Review 1.  The changing landscape of phase I trials in oncology.

Authors:  Kit Man Wong; Anna Capasso; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2015-11-10       Impact factor: 66.675

Review 2.  A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.

Authors:  James T Yurkovich; Qiang Tian; Nathan D Price; Leroy Hood
Journal:  Nat Rev Clin Oncol       Date:  2019-10-16       Impact factor: 66.675

3.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.

Authors:  Oliver Jonas; Heather M Landry; Jason E Fuller; John T Santini; Jose Baselga; Robert I Tepper; Michael J Cima; Robert Langer
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

4.  Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey.

Authors:  Pinkie Chambers; Kenneth K C Man; Vivian W Y Lui; Sheila Mpima; Paola Nasuti; Martin D Forster; Ian C K Wong
Journal:  JCO Oncol Pract       Date:  2020-03-11

5.  Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

Authors:  J Rodon; J C Soria; R Berger; G Batist; A Tsimberidou; C Bresson; J J Lee; E Rubin; A Onn; R L Schilsky; W H Miller; A M Eggermont; J Mendelsohn; V Lazar; R Kurzrock
Journal:  Ann Oncol       Date:  2015-04-23       Impact factor: 32.976

6.  Complex behaviours--new targets against cancer.

Authors:  Dali Tong; Jun Jiang
Journal:  Nat Rev Clin Oncol       Date:  2012-12-18       Impact factor: 66.675

7.  The microenvironment and resistance to personalized cancer therapy.

Authors:  Shigeo Masuda; Juan Carlos Izpisua Belmonte
Journal:  Nat Rev Clin Oncol       Date:  2012-12-18       Impact factor: 66.675

Review 8.  Challenges and opportunities in childhood cancer drug development.

Authors:  Robin E Norris; Peter C Adamson
Journal:  Nat Rev Cancer       Date:  2012-10-11       Impact factor: 60.716

Review 9.  Tumor heterogeneity in the clinic: is it a real problem?

Authors:  Filip Janku
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

Review 10.  Building a personalized medicine infrastructure at a major cancer center.

Authors:  Funda Meric-Bernstam; Carol Farhangfar; John Mendelsohn; Gordon B Mills
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.